{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T22:13:56Z","timestamp":1791756836961,"version":"4.3.4"},"reference-count":11,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.urolonc.2025.10.016","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T06:41:28Z","timestamp":1763361688000},"page":"118.e1-118.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Outcomes of enfortumab vedotin plus pembrolizumab in patients with advanced urothelial cancer and severe renal dysfunction"],"prefix":"10.1016","volume":"44","author":[{"given":"Henry K.","family":"Litt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronac","family":"Mamtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1872-6307","authenticated-orcid":false,"given":"Ryan D.","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2025.10.016_bib0001","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab Vedotin and Pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2025.10.016_bib0002","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.eururo.2024.08.012","article-title":"Real-world uptake of Enfortumab Vedotin plus Pembrolizumab after US Food and Drug Administration approval among patients with advanced urothelial cancer","volume":"86","author":"Mamtani","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.10.016_bib0003","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab Vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Eng J Med"},{"key":"10.1016\/j.urolonc.2025.10.016_bib0004","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S1470-2045(21)00094-2","article-title":"Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV\u2011201): a multicentre, single-arm, phase 2 trial","volume":"22","author":"Yu","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2025.10.016_bib0005","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1080\/14796694.2024.2342227","article-title":"Management of urothelial cancer in patients with chronic kidney disease receiving platinum-based chemotherapy","volume":"20","author":"T O\u2019Dwyer","year":"2024","journal-title":"Future Oncol"},{"key":"10.1016\/j.urolonc.2025.10.016_bib0006","doi-asserted-by":"crossref","first-page":"4460","DOI":"10.1111\/1475-6773.12872","article-title":"Development and validation of a high-quality composite real-world mortality endpoint","volume":"53","author":"Curtis","year":"2018","journal-title":"Health Services Res"},{"key":"10.1016\/j.urolonc.2025.10.016_bib0007","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1093\/annonc\/mdr156","article-title":"Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma","volume":"23","author":"Galsky","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2025.10.016_bib0008","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s40262-024-01369-0","article-title":"Clinical pharmacology of the antibody-drug conjugate enfortumab Vedotin in advanced urothelial carcinoma and other malignant solid tumors","volume":"63","author":"Tang","year":"2024","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"10.1016\/j.urolonc.2025.10.016_bib0009","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.19524","article-title":"Survival trends in urothelial cancer before and after ICIs and antibody drug conjugates","volume":"8","author":"Lian","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.urolonc.2025.10.016_bib0010","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41571-019-0167-7","article-title":"Real-world data: towards achieving the achievable in cancer care","volume":"16","author":"Booth","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2025.10.016_bib0011","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41591-024-03352-5","article-title":"Evaluating generalizability of oncology trial results to real-world patients using machine learning-based trial emulations","volume":"31","author":"Orcutt","year":"2025","journal-title":"Nat Med"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925004156?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925004156?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T12:30:07Z","timestamp":1769257807000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143925004156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":11,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1078143925004156"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.10.016","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of enfortumab vedotin plus pembrolizumab in patients with advanced urothelial cancer and severe renal dysfunction","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.10.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}